1The Dartmouth Institute of Health Policy and Clinical Practice, Lebanon, New Hampshire, USA
2Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, California, USA
3Crohn’s & Colitis Foundation of America, New York, New York, USA
4Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
Correspondence: Lisa C. Johnson, MBA, The Dartmouth Institute for Health Policy and Clinical Practice, 1 Medical Center Drive, WTRB Level 5, Lebanon, New Hampshire 03766, USA. E-mail: [email protected]
Guarantor of the article: Corey A. Siegel, MD, MS.
Specific author contributions: Writing of the manuscript and final manuscript approval: Lisa C. Johnson; conception of article, critical review, and final manuscript approval: Corey A. Siegel; critical review and manuscript editing: Gil Y. Melmed, Eugene C. Nelson, Megan M. Holthoff, S. Alandra Weaver, Tamara S. Morgan.
Financial support: Crohn’s & Colitis Foundation of America (Grant #3372). Crohn’s & Colitis Foundation IBD Qorus is supported in part by funding from AbbVie, Janssen Biotech, Inc., Luitpold, Nestlé Health Sciences, Pfizer, Inc., Shire, and Takeda Pharmaceuticals, U.S.A., Inc.
Potential competing interests: Corey A. Siegel: Consultant/Advisory Board of AbbVie, Amgen, Celgene, Lilly, Janssen, Sandoz, Pfizer, Prometheus, Takeda, UCB; Speaker for CME Activities: American Regent, AbbVie, Janssen, Pfizer, Takeda; Grant Support: CCFA (#3372-510516), AHRQ (1R01HS021747-01), AbbVie, Janssen, Pfizer, Takeda. Gil Y. Melmed: Consultant for Abbvie, Celgene, Jannsen, Luitpold, Medtronic, Pfizer, Takeda, UCB; Research: Prometheus Labs; Grant Support: CCFA (#3372-510516). Eugene C. Nelson: Grant Support: CCFA (#3372-511692). S. Alandra Weaver, MPH: Employed by CCFA. The remaining authors declare no conflict of interest.
